BridgeBio Pharma
BBIO
BridgeBio Pharma (BBIO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.78
- EPS estimate
- −$0.58
- EPS surprise
- −35.51%
- Revenue surprise
- +10.31%
- Revenue
- $243.7M
- Revenue estimate
- $220.9M
- Reported
- Aug 10, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 10, 2026 | −$0.58 | −$0.78 | −35.51% | $243.7M | SEC |
| Q1 2026 | May 7, 2026 | −$0.67 | −$0.84 | −25.49% | $194.5M | SEC |
| Q4 2025 | Feb 24, 2026 | −$0.71 | −$1.00 | −40.17% | $154.2M | SEC |
| Q3 2025 | Oct 29, 2025 | −$0.89 | −$0.95 | −6.25% | $120.7M | SEC |
| Q2 2025 | Aug 5, 2025 | −$0.79 | −$0.95 | −19.74% | $110.6M | SEC |
| Q1 2025 | Apr 29, 2025 | −$0.92 | −$0.88 | +4.13% | $116.6M | SEC |
| Q4 2024 | Feb 20, 2025 | −$1.12 | −$1.40 | −24.98% | $5.9M | SEC |
| Q3 2024 | Nov 12, 2024 | −$1.00 | −$0.86 | +14.28% | $2.7M | SEC |
| Q2 2024 | Aug 1, 2024 | −$1.00 | −$0.39 | +60.93% | $2.2M | SEC |
| Q1 2024 | May 2, 2024 | −$0.74 | −$0.20 | +72.86% | $211.1M | SEC |
| Q4 2023 | Feb 22, 2024 | −$0.87 | −$0.96 | −10.48% | $1.7M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.79 | −$1.08 | −36.12% | $4.1M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.80 | −$0.98 | −22.68% | $1.6M | SEC |
| Q1 2023 | May 4, 2023 | −$0.82 | −$0.92 | −11.85% | $1.8M | SEC |
| Q4 2022 | Feb 23, 2023 | −$0.84 | −$0.92 | −9.77% | $1.9M | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.97 | −$0.93 | +3.94% | $338,000.00 | SEC |
| Q2 2022 | Aug 4, 2022 | −$0.56 | −$0.07 | +87.43% | $73.7M | SEC |
| Q1 2022 | May 5, 2022 | −$1.09 | −$1.35 | −24.28% | $1.7M | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.88 | −$1.01 | −14.53% | $12.9M | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.91 | −$1.06 | −15.90% | $2.3M | SEC |
Quarterly revenue
Frequently asked questions
When did BridgeBio Pharma (BBIO) last report earnings?
BridgeBio Pharma last reported on Aug 10, 2026, covering fiscal Q2 2026.
Did BBIO beat earnings estimates?
No. BridgeBio Pharma reported EPS of −$0.78 for Q2 2026 against a −$0.58 estimate — a 35.51% miss.
How much revenue did BBIO report last quarter?
BridgeBio Pharma reported $243.7M in revenue for Q2 2026, against a consensus estimate of $220.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.